← Back to Screener
Edgewise Therapeutics, Inc. Common Stock (EWTX)
Price$35.59
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)28.75%
Price vs S&P 500 (4W)0.77%
VGM Score87.62
Market Capitalization$3.83B
All Metrics
Book Value / Share (Quarterly)$4.59
P/TBV (Annual)1.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.39
Price vs S&P 500 (YTD)35.26%
EPS (TTM)$-1.66
10-Day Avg Trading Volume1.83M
EPS Excl Extra (TTM)$-1.66
EPS (Annual)$-1.63
ROI (Annual)-32.13%
Cash / Share (Quarterly)$4.65
ROA (Last FY)-30.36%
EBITD / Share (TTM)$-1.86
ROE (5Y Avg)-25.56%
Cash Flow / Share (Annual)$-1.36
P/B Ratio7.76x
P/B Ratio (Quarterly)6.86x
Net Income / Employee (Annual)$-1,149,300
ROA (TTM)-31.04%
EPS Incl Extra (Annual)$-1.63
Current Ratio (Annual)19.85x
Quick Ratio (Quarterly)22.16x
3-Month Avg Trading Volume1.08M
52-Week Price Return140.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.58
52-Week High$40.77
EPS Excl Extra (Annual)$-1.63
CapEx CAGR (5Y)5.06%
26-Week Price Return36.67%
Quick Ratio (Annual)19.37x
13-Week Price Return25.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.61x
Enterprise Value$3.80B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.99
3-Month Return Std Dev68.96%
Net Income / Employee (TTM)$-1,205,500
ROE (Last FY)-32.13%
EPS Basic Excl Extra (Annual)$-1.63
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.66
ROI (TTM)-32.55%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.48
Price vs S&P 500 (52W)115.78%
Year-to-Date Return43.42%
5-Day Price Return-11.60%
EPS Normalized (Annual)$-1.63
ROA (5Y Avg)-24.15%
Month-to-Date Return4.19%
Cash Flow / Share (TTM)$-1.39
EBITD / Share (Annual)$-1.84
ROI (5Y Avg)-25.56%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.66
P/TBV (Quarterly)1.41x
P/B Ratio (Annual)5.03x
Book Value / Share (Annual)$4.92
Price vs S&P 500 (13W)17.11%
Beta0.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.55%
52-Week Low$12.15
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.46est. -0.50
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EWTXEdgewise Therapeutics, Inc. Common Stock | — | — | A | $35.59 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac conditions. Its lead candidate, Sevasemten, is an oral small molecule designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is advancing additional product candidates targeting muscle disease across its pipeline.